Compare OWLT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | LEXX |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.5M | 14.5M |
| IPO Year | N/A | N/A |
| Metric | OWLT | LEXX |
|---|---|---|
| Price | $15.27 | $0.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 352.0K | ★ 1.4M |
| Earning Date | 11-13-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,640,000.00 | $705,923.00 |
| Revenue This Year | $36.68 | $13.35 |
| Revenue Next Year | $22.20 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 26.81 | ★ 52.05 |
| 52 Week Low | $2.75 | $0.48 |
| 52 Week High | $16.82 | $2.43 |
| Indicator | OWLT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 31.42 |
| Support Level | $11.92 | $0.48 |
| Resistance Level | $14.92 | $0.70 |
| Average True Range (ATR) | 1.24 | 0.12 |
| MACD | -0.04 | -0.06 |
| Stochastic Oscillator | 68.37 | 9.27 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.